These study results suggested that a longer time to surgery does not lower overall survival for women with early-stage breast cancer who had to delay operations due to the COVID-19 pandemic.
The FDA has approved alectinib for the adjuvant treatment of patients with ALK-positive non-small cell lung cancer with tumors that are least 4 cm or…
Those aged 18 to 40 years with invasive, HER2-positive breast cancer showed a survival benefit from upfront surgery over neoadjuvant chemotherapy.
TLX101 is currently under assessment as a treatment for glioma in the IPAX-2 and IPAX-Linz studies.
Results from the INSITE trial support the utility of pegulicianine fluorescence-guided surgery during breast cancer surgery.
An increased TIL count in the breast tissue was associated with improved distant recurrence-free survival in patients with triple-negative breast cancer.
The phase 3 TOPAZ-1 trial of durvalumab plus chemotherapy showed a significant benefit vs chemotherapy alone for patients with advanced biliary tract cancer.
A proteogenomic analysis found savolitinib plus osimertinib elicited a response in patients with EGFR-mutated, MET-amplified advanced NSCLC.
Pediatric patients with acute lymphoblastic leukemia/lymphoma were less likely to have severe COVID-19 infection.
Phase 2 findings support olutasidenib as a potentially “valuable” treatment option in IDH1-mutated acute myeloid leukemia.
Beth Faiman, PhD, MSN, describes the role of a GRPC5D-targeting bispecific antibody, talquetamab, in the treatment of patients with relapsed/refractory multiple myeloma.
